Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Researchers Advise Caution in Use of SRC Inhibitors to Treat Bladder Cancer

By R&D Editors | March 26, 2009

Researchers at the University of Virginia Health System have found that one of the genes commonly thought to promote the growth and spread of some types of cancers is in fact beneficial in bladder cancer – a discovery that could alter the way bladder cancers are treated in the future. 

The study shows that in bladder cancer the SRC gene may help rather than hinder the natural ability of cells to suppress aggressive tumor growth.  

‘We found that SRC modifies a recently discovered metastasis suppressor gene called RhoGDI2 making it more potent at slowing bladder cancer’s ability to metastasize,’ says lead author Dan Theodorescu, MD, PhD, professor of urologic oncology and molecular physiology at the UVA School of Medicine. 

SRC is a type of oncogene. In most cancers SRC has been shown to promote tumor development and contribute to the spread of cancer. Other genes, called metastasis suppressor genes, block this activity, and only when their levels are reduced is cancer able to spread.

In the study, researchers analyzed human bladder cancer and discovered that SRC levels diminish as bladder cancer progresses. They also found that reduced SRC levels and significant levels of the metastasis suppressor gene, RhoGD12, appear mutually exclusive in individual tumors – providing evidence that both genes are likely involved in the process leading to suppression of bladder cancer metastases.

‘Our findings have important implications for the use of targeted therapeutic agents that inhibit SRC in bladder cancer and highlight the general importance of personalizing therapy in cancer,’ says Theodorescu. ‘Our data suggest using caution for their use in treating bladder cancer until more studies are carried out to define the implications of this form of therapy in bladder cancer.’

Release Date: March 25, 2009
Source: University of Virginia Health System

Related Articles Read More >

professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
Health-related innovation in Morocco highlighted by resident inventor patenting activity
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE